标题：朱海珍
湖南大学——朱海珍
简介朱海珍， 男，出生于湖北，汉族，群众，1969年4月生，2008年教授，分子医学系系主任，医学博士学位，研究生学历。  博士生导师[1]学习经历1990年毕业于白求恩医科大学， 获得医学学士学位
1997年毕业于同济医科大学， 获得医学硕士学位
2000年毕业于 华中科技大学同济医学院  获得医学博士学位工作经历1990-1994 同济医科大学 助教
2000-2005 美国佛罗里达大学 博士后
2005-2009 美国佛罗里达大学 助理科学家
2008-现在 湖南大学 教授主要研究方向分子病毒学与分子肿瘤学教学主讲生物学院本科生  《药理学》课程
主讲生物学院研究生 《专业英语》课程
科研情况：
1.、“核酸适体在丙型病毒性肝炎早期诊断和靶向治疗中的应用基础研究”（2009ZX10004-312） “艾滋病和病毒性肝炎等重大传染病防治”国家科技重大专项 768万元
2、“丙型病毒性肝炎发病机制探讨” 教育部新世纪优秀人才支持计划 50万元
3、“肝炎病毒感染小鼠模型的构建” 湖南省科研条件创新专项 5万元
科研论文及专著
代表性论文：1. Eksioglu E, Bess J, Zhu H, Xu Y, Dong H, Elyar J, Nelson DR, Liu C. Hepatitis C virus modulates human monocyte-derived dendritic cells. J Vir Hepat 2010; 17:757-769 (IF:3.348)
2. Eksioglu EA, Bess J, Jones G, Dettloff J, Dangmeon P, Dong HJ, Zhu H, Firpi R, Xu Y, Nelson DR, Liu C. Characterization of anti-HCV antibodies in IL-10 treated patients. Viral Immunology 2010;23:359-368 (IF:1.779)
3. Zhu H, Elyar J, Foss R, Hemming A, Hall E, Lecluyse EL, Liu C. Primary human hepatocyte culture for HCV study. Methods Mol Biol, 2009 510:373-382.
4. Kenworthy R, Lambert D, Yang F, Wang N, Chen Z,Zhu H, Zhu F, Liu C, Li K, Tang H. Short-hairpin RNAs delivered by lentiviral vector transduction trigger RIG-I-mediated IFN activation. Nucleic Acids Res.2009;37:6587-6599 (IF: 7.48)
5. Wu H, Zhu H, Zhuang J, Liu C, Cao YC. Water-soluble nanocrystals through dual-interaction ligands. Angew Chem Int Edit. 2008; 47:3730-34. (IF: 11.829)Butler SL, Dong H, Cardona D, Jia M, Zheng R, Zhu H, Crawford JM, Liu C. The antigen for Hep Par 1 antibody is the urea cycle enzyme carbamoyl phosphate synthetase 1. Lab Invest 2008; 88:78-88. (IF: 4.602)
6. Zhu H, Dong H, Eksioglu E, Hemming A, Cao M, Crawford CM, Nelson DR, Liu C. Hepatitis C virus triggers cell death through innate intracellular antiviral defense system. Gastroenterology 2007; 133:1649-1659 (IF: 12.899)
7. Liu C, Zhu H, Subramanian MG, Moore PA, Xu Y, Nelson DR. Anti-hepatitis C virus activity of albinterferon alfa-2b in cell culture. Hepatology Research. 2007; 37:941-947. (IF: 1.540)
8. Cao M, Cabrera R, Xu Y, Firpi R, Zhu H, Liu C, Nelson DR. Hepatocellular carcinoma cell supernatants increase expansion and function of CD4(+)CD25(+) regulatory T cells. Lab Invest. 2007, 87:582-590. (IF: 4.602)
9. *Firpi RJ, Zhu H, Morelli G, Abdelmalek MF, Reed AI, Liu C, Nelson DR. Cyclosporine suppresses hepatitis C virus in vitro and increase the chance of sustained virological response after liver transplantation. Liver Transplantation 2006, 12:51-57 (see Editorial on Page 19-21) (IF: 4.085)
10. Zhu H, Butera M, Nelson DR and Liu C. Novel type I Interferon IL-28A suppresses hepatitis C viral RNA replication. Virology J  2005, 2:80 (IF: 2.435)
11. Zhu H, Nelson DR, Crawford JM and Liu C. Defective JAK-STAT activation in host cells confers hepatitis C viral interferon-alpha resistance. J of Interferon and Cytokine Res 2005, 25(9): 528-539 (IF: 1.627)
12. Rufforny I, Wilkinson EJ, Liu C, Zhu H, Buteral M, Massoll NA. Human papillomavirus infection and p16 (INK4a) protein expression in vulvar intraepithelial neoplasia and invasive squamous cell carcinoma. J Lower Genital Tract Disease. 2005, 9(2):108-113.
13. Zhu H, Shang X, Terada N, Liu C. STAT3 induces anti-hepatitis C viral activity in liver cells. Biochem and Biophys Res Commun 2004; 324:518-528 (IF: 2.55)
14. Shang XZ, Zhu H, Lin K, Tu Z, Chen J, Nelson DR and Liu C. Stabilized b-catenin promotes hepatocyte proliferation and inhibits TNFa-induced apoptosis. Laboratory Investigation 2004; 84:332-341 (IF: 4.602)
15. Nelson DR, Tu Z, Soldevila-Pico C, Abdelmalek M, Zhu H, Xu YL, Cabrera R, Liu C and Davis G. Long-term interleukin10 therapy in chronic hepatitis C patients has a proviral and anti-inflammatory effect. Hepatology 2003; 38:859-868 (IF: 11.355)
16. *Liu C, Zhu H, Tu Z, Xu YL and Nelson DR. CD8+ T cell interaction with HCV replicon cells: evidence for both cytokine- and cell—mediated antiviral activity. Hepatology 2003; 37:1335-1342 (IF:11.355)
17. *Zhu H, Zhao H, Collins CD, Eckerrode SE, Ruan Q, Mcindoe RA, Crawford JM, Nelson DR, She JX and Liu C. Gene expression associated with interferon alfa antiviral activity in an HCV replicon cell line. Hepatology 2003; 37:1180-1188 (see Editorial on Page 975-978) (IF: 11.355)
18. Zhu H and Liu C. Interleukin-1 inhibit hepatitis C virus subgenomic RNA replication by activation of extracellular regulated kinase pathway. J Virology 2003; 77:5493-5498 (IF: 5.15)
19. Zhu HZ, Ruan YB, Wu ZB and Zhang CM. Kupffer cell and apoptosis in experimental HCC. World J Gastroenterol 2000; 6:405-407(IF:2.092)
20. Zhu H, Ruan Y, Yang M, Wu Z, Zhang C. The influence of Kupffer cells on apoptosis in the experimental hepatocellular carcinoma. Chinese Journal of Histochemistry and Cytochemistry 2000; 9:138-141
21. Staudacher C, Chiappa A, Zbar AP, Bertani E, Biella F, Haizhen Z. Evalution of risk factors in the development of postoperative complications in patients undergoing liver resection for cancer. Chir Itl 2000; 52:123-129
22. Zhu H, Ruan Y, Wu Z. The influence of Kupffer cells on the expression of apoptosis related genes in experimental hepatocellular carcinoma. Acta Univ Med Tongji 2000; 29:97-99
23. Zhu H, Ruan Y, Yang M, Wu Z and Ivankovic S. The role of Kupffer cells in experimental hepatocarcinogenesis: a microscopic, light and electron microscopic observation. Acta Univ Med Tongji 1998; 27:420-422, 430
24. Zhu H, Ruan Y, Wu Z. The influence of Kupffer cells on experimental hepatocarcinogenesis. Zhonghua Bing Li Xue Za Zhi [Chin J Pathol] 1998; 27: 102-104
学术专著目录
1.Zhu H, Elyar J, Foss R, Hemming A, Hall E, Lecluyse EL, Liu C. Chapter 28 Primary human hepatocyte culture for HCV study. Hepatitis C: Methods and Protocols (2Edition). Vol 510Methods Mol Biol, p373-382. The Humana Press, 2009专利Human liver cancer cell line. International Application No. PCT/US2007/ 006722.[2]